In this episode, we explore how Lytix Biopharma is advancing a new kind of cancer treatment designed to both destroy tumors and train the immune system to fight back. Dr. Øystein Rekdal joins Dr. Susan McDonald to discuss the science behind LTX-315, a first-in-class oncolytic peptide, and its ability to trigger systemic immune responses even in heavily pretreated patients. From late-stage melanoma to earlier intervention strategies, this conversation highlights how reprogramming the tumor microenvironment could open new doors for patients and redefine the future of immunotherapy.